Back D J, Breckenridge A M, Crawford F E, Orme M L, Rowe P H
Br J Pharmacol. 1980 Jul;69(3):441-52. doi: 10.1111/j.1476-5381.1980.tb07033.x.
1 The effect of phenobarbitone on the single dose pharmacokinetics of the synthetic steroids, ethinyloestradiol (EE2) and norethisterone, has been studied in the rabbit and rat. 2 EE2 is subject to an extensive first pass effect (96%). The plasma clearance of EE2 approaches total hepatic blood flow. It is suggested that a secondary peak in EE2 plasma concentration time curves at 5 h is due to enterohepatic recycling. Phenobarbitone had no effect on plasma EE2 concentrations following intravenous administration and produced a variable decrease after oral administration. 3 In phenobarbitone-treated rabbits, following intravenous administration of norethisterone there was no significant change in the area under the curve (AUC) compared to controls. In contrast, following oral administration of norethisterone to treated rabbits, the AUC was 20% and the peak plasma concentration 17% of that in controls. 4 The data in rabbits are consistent with drugs which are highly extracted by the liver. 5 In rats, phenobarbitone had no effect on plasma norethisterone concentrations following intravenous or hepatic portal (bolus) administration, but caused a decrease in systemic availability after both infusion into the portal vein (over a period of 5 min) and oral administration. 6 It is concluded that the rate of delivery of norethisterone to the liver is important in determining whether or not enzyme induction will cause an increased first pass effect. 7 Phenobarbitone caused an increase in conjugation of norethisterone in the gastrointestinal tract of rats.
1 已在兔和大鼠中研究了苯巴比妥对合成甾体类药物炔雌醇(EE2)和炔诺酮单次给药药代动力学的影响。2 EE2存在广泛的首过效应(96%)。EE2的血浆清除率接近肝脏总血流量。有人认为,EE2血浆浓度-时间曲线在5小时出现的第二个峰值是由于肠肝循环所致。静脉给药后,苯巴比妥对血浆EE2浓度无影响,口服给药后则使其出现不同程度的下降。3 在经苯巴比妥处理的兔中,静脉注射炔诺酮后,与对照组相比,曲线下面积(AUC)无显著变化。相比之下,给经处理的兔口服炔诺酮后,其AUC为对照组的20%,血浆峰值浓度为对照组的17%。4 兔的实验数据与肝脏高摄取药物的情况一致。5 在大鼠中,静脉注射或经肝门静脉(推注)给药后,苯巴比妥对血浆炔诺酮浓度无影响,但在门静脉输注(持续5分钟)和口服给药后均导致全身药物可利用性降低。6 得出的结论是,炔诺酮向肝脏的输送速率对于确定酶诱导是否会导致首过效应增加很重要。7 苯巴比妥使大鼠胃肠道中炔诺酮的结合增加。